
NCGC00378430
CAS No. 920650-00-6
NCGC00378430( —— )
Catalog No. M24968 CAS No. 920650-00-6
NCGC00378430 is a potent?SIX1/EYA2?interaction inhibitor that disrupts the SIX1/EYA2 complex, EMT, and Metastasis.
Purity : >98% (HPLC)






Size | Price / USD | Stock | Quantity |
5MG | 178 | In Stock |
![]() ![]() |
10MG | 295 | In Stock |
![]() ![]() |
25MG | 502 | In Stock |
![]() ![]() |
50MG | 709 | In Stock |
![]() ![]() |
100MG | 1008 | In Stock |
![]() ![]() |
200MG | Get Quote | In Stock |
![]() ![]() |
500MG | Get Quote | In Stock |
![]() ![]() |
1G | Get Quote | In Stock |
![]() ![]() |
Biological Information
-
Product NameNCGC00378430
-
NoteResearch use only, not for human use.
-
Brief DescriptionNCGC00378430 is a potent?SIX1/EYA2?interaction inhibitor that disrupts the SIX1/EYA2 complex, EMT, and Metastasis.
-
DescriptionNCGC00378430 is a potent?SIX1/EYA2?interaction inhibitor that disrupts the SIX1/EYA2 complex, EMT, and Metastasis.
-
In VitroWestern Blot Analysis Cell Line:T47D cells Concentration:20 μM Incubation Time:3 days Result:Blocked TGF-β induced activation of p-Smad3, upregulation of FN1, and downregulation of E-CAD.
-
In VivoAnimal Model:6-8 week old NSG mice with MCF7 tumor cellsDosage:25 mg/kg Administration:Local Injection to the site of tumor; every other day; from day 3 until the day 21 Result:Dramatically decreased distant metastatic burden compared to vehicle treatment.Had no growth inhibitory effect.Animal Model:Mice Dosage:20 mg/kg (Pharmacokinetic Analysis) Administration:IV Result:Had a T1/2α of 0.25 hours, a CL of 6.19 L/hr?kg, a Vss of 4.08 L/kg, a Cmax of 6703 ng/mL and an AUC of 3234 ng/mL?hr.
-
Synonyms——
-
PathwayOthers
-
TargetOther Targets
-
RecptorSIX1-EYA2
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number920650-00-6
-
Formula Weight441.5
-
Molecular FormulaC22H23N3O5S
-
Purity>98% (HPLC)
-
SolubilityDMSO:90 mg/mL?(203.85 mM;?Need ultrasonic)
-
SMILESO=C(NC1=CC=C(OC)C(S(=O)(N2CCOCC2)=O)=C1)C3=CC=CC(N4C=CC=C4)=C3
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Hengbo Zhou, et al. Identification of a Small-Molecule Inhibitor That Disrupts the SIX1/EYA2 Complex, EMT, and Metastasis. Cancer Res. 2020 Jun 15;80(12):2689-2702.
molnova catalog



related products
-
GSK-1520489A
GSK-1520489A is an active PKMYT1 inhibitor.
-
2-Methylbenzhydrol
Used as pharmaceutical intermediates.
-
Amylin, amide, rat
Amylin is a peptide that displays 50% homology with calcitonin gene-related peptide (CGRP), Amylin is colocalized with somatostatin in endocrine cells of the gastric fundus. In isolated mouse stomach, amylin caused a concentration-dependent decrease in acid secretion.